Ameriprise’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-38,956
| Closed | -$5.14M | – | 4171 |
|
|
2025
Q1 | $5.14M | Sell |
38,956
-483,607
| -93% | -$60.3M | ﹤0.01% | 2297 |
|
|
2024
Q4 | $43.6M | Sell |
522,563
-7,633
| -1% | -$627K | 0.01% | 906 |
|
|
2024
Q3 | $38.8M | Buy |
530,196
+186,375
| +54% | +$14M | 0.01% | 967 |
|
|
2024
Q2 | $23.5M | Sell |
343,821
-68,375
| -17% | -$4.74M | 0.01% | 1178 |
|
|
2024
Q1 | $28.5M | Buy |
412,196
+308,009
| +296% | +$21.2M | 0.01% | 1086 |
|
|
2023
Q4 | $7.46M | Buy |
104,187
+31,667
| +44% | +$1.82M | ﹤0.01% | 2039 |
|
|
2023
Q3 | $3.78M | Sell |
72,520
-5,200
| -7% | -$303K | ﹤0.01% | 2493 |
|
|
2023
Q2 | $4.92M | Sell |
77,720
-3,009
| -4% | -$188K | ﹤0.01% | 2356 |
|
|
2023
Q1 | $4.37M | Buy |
80,729
+31,245
| +63% | +$1.51M | ﹤0.01% | 2413 |
|
|
2022
Q4 | $2.62M | Buy |
49,484
+42,117
| +572% | +$2.11M | ﹤0.01% | 2690 |
|
|
2022
Q3 | $343K | Sell |
7,367
-1,352
| -16% | -$70.6K | ﹤0.01% | 3536 |
|
|
2022
Q2 | $498K | Buy |
8,719
+1,235
| +17% | +$70K | ﹤0.01% | 3394 |
|
|
2022
Q1 | $458K | Buy |
+7,484
| New | +$389K | ﹤0.01% | 3519 |
|
|
2020
Q1 | – | Sell |
-8,386
| Closed | -$288K | – | 3757 |
|
|
2019
Q4 | $288K | Buy |
+8,386
| New | +$101K | ﹤0.01% | 3488 |
|
|
2019
Q3 | – | Sell |
-11,500
| Closed | -$149K | – | 3779 |
|
|
2019
Q2 | $149K | Buy |
+11,500
| New | +$147K | ﹤0.01% | 3622 |
|
|
2016
Q3 | – | Sell |
-8,460
| Closed | -$328K | – | 3847 |
|
|
2016
Q2 | $328K | Buy |
8,460
+150
| +2% | +$5.39K | ﹤0.01% | 3347 |
|
|
2016
Q1 | $231K | Sell |
8,310
-52,508
| -86% | -$1.75M | ﹤0.01% | 3476 |
|
|
2015
Q4 | $3.27M | Buy |
60,818
+18,359
| +43% | +$926K | ﹤0.01% | 2325 |
|
|
2015
Q3 | $1.7M | Sell |
42,459
-5,261
| -11% | -$172K | ﹤0.01% | 2708 |
|
|
2015
Q2 | $1.52M | Buy |
+47,720
| New | +$1.21M | ﹤0.01% | 2908 |
|
|
2014
Q4 | – | Sell |
-5
| Closed | – | – | 4478 |
|
|
2014
Q3 | $0 | Buy |
+5
| New | +$75 | ﹤0.01% | 5912 |
|
Other funds holding ITCI
KIM
HNB
Ameriprise's ITCI Position: Q2 2025 in Review
Ameriprise sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 38,956 shares — an estimated $5.14M sold.
Ameriprise first reported a position in ITCI in Q3 2014 and held it in 21 quarters. The position peaked at $43.6M in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Ameriprise reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Ameriprise sold 38,956 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $5.14M.
- Ameriprise first reported a position in Intra-Cellular Therapies Inc. in Q3 2014 and held it in 21 quarters.
- Ameriprise's Intra-Cellular Therapies Inc. position peaked at $43.6M in Q4 2024.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Ameriprise's 13F filing for Q2 2025, filed 14 Aug 2025.